What is ADB-BUTINACA?
ADB-BUTINACA is potent indole-based cannabinoid and is an agonist of the CB1 and CB2 receptor with EC50 values of 0.52 nM and 0.88 nM respectively. Has been is closely related to MDMB-BUTINACA and results in laboratory tests show many similar reactions. ADB-Butinaca
Showing its potency in tests ADB-BUTINACA in theory will provide results such as, relaxation, mood enhancement, Euphoria and body lightness.
Always store in a cool, dry place for maximum shelf-life. This product is intended for forensic and research applications only. It is therefore NOT intended for human consumption or in-vivo testing of any kind on animals or any living organism.
Kindly let us know so we can ship discretely to your location without it passing through checks . Always reach out through the inquiry form and note that all payments will be process using any acceptable crypto currency but we recommend using bitcoin, ether, bch
ADB-BINACA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products. It was originally developed by Pfizer as a potential analgesic, and is a potent agonist of the CB1 receptor with a binding affinity (Ki) of 0.33 nM and an EC50 of 14.7 nM.
ADB-BUTINACA
 |
|
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C18H26N4O2 |
| Molar mass | 330.432 g·mol−1 |
| 3D model (JSmol) | |
The analogue with a 1-butyl substitution on the indazole ring rather than 1-benzyl has also been sold as a designer drug under the name ADB-BINACA, but is now more commonly referred to as ADB-BUTINACA to avoid confusion with the benzyl compound. It is a similarly potent CB1 agonist, with an EC50 of 6.36 nM
Reviews
There are no reviews yet.